KVUE

NYSE·Consumer Defensive·Household & Personal Products·USA

Latest market price

19.28

+0.38+2.01%

Overview Short InterestFilings

KVUEQT53Kenvue Inc.·NYSE

Overview Short InterestFilings

19.28+2.01%

News

Up 2.0% — US FDA approves over-the-counter Tylenol combination pill for pain relief (reuters.com).

Medium confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

KMB+2.23%$109.70 EL+0.46%$80.29 CHD+1.51%$97.64 CL+0.74%$90.75 CLX+1.87%$95.55 UL+1.21%$60.94 REYN+1.59%$25.61 ELF+1.59%$77.36

Snapshot

Index	S&P 500	P/E	22.68	EPS (ttm)	0.85	Insider Own	1.64%	Shs Outstand	1.92B	Perf Week	1.58%

Market Cap	37.02B	Forward P/E	15.29	EPS next Y	1.26	Insider Trans	-0.13%	Shs Float	1.92B	Perf Month	2.55%

Enterprise Value	44.60B	PEG	0.42	EPS next Q	-	Inst Own	-	Short Float	3.21%	Perf Quarter	10.23%

Income	1.63B	P/S	2.42	EPS this Y	40.82%	Inst Trans	-	Short Ratio	3.07	Perf Half Y	8.62%

Sales	15.29B	P/B	3.49	EPS next Y	5.36%	ROA	6.04%	Short Interest	61.56M	Perf YTD	11.77%

Book/sh	-	P/C	16.38	EPS next 5Y	4.15%	ROE	15.18%	52W High	22.87 -15.70%	Perf Year	-14.46%

Cash/sh	-	P/FCF	20.31	EPS past 3/5Y	-11.05% -	ROIC	9.76%	52W Low	14.02 37.52%	Perf 3Y	-22.88%

Dividend Est.	0.83 (4.30%)	EV/EBITDA	14.07	Sales past 3/5Y	0.39% 0.89%	Gross Margin	58.37%	Volatility	1.29% 1.93%	Perf 5Y	-

Dividend TTM	0.83 (4.30%)	EV/Sales	2.92	EPS Y/Y TTM	57.41%	Oper. Margin	19.62%	ATR (14)	0.40	Perf 10Y	-

Dividend Ex-Date	May 13, 2026	Quick Ratio	0.70	Sales Y/Y TTM	-1.05%	Profit Margin	10.61%	RSI (14)	57.50	Recom	2.71

Dividend Gr. 3/5Y	-	Current Ratio	0.98	EPS Q/Q	33.33%	SMA20	0.47%	Beta	0.14	Target Price	18.75

Payout	0.37%	Debt/Eq	0.82	Sales Q/Q	4.49%	SMA50	5.39%	Rel Volume	0.82	Prev Close	18.90

Employees	22,000	LT Debt/Eq	0.66	Earnings	Aug 06	SMA200	10.53%	Avg Volume	20.17M	Price	19.28

IPO Date	May 04, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.10% 1.67%	Net Debt/EBITDA	2.39	Volume	16,441,182	Change	2.01%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-21-26	Reiterated	Barclays	Equal Weight	$18 → $19
Jul-16-26	Reiterated	UBS	Neutral	$19 → $20
Apr-14-26	Reiterated	Barclays	Equal Weight	$17 → $18
Feb-18-26	Reiterated	UBS	Neutral	$17 → $19
Feb-18-26	Reiterated	Canaccord Genuity	Hold	$15 → $18
Jan-30-26	Downgrade	Jefferies	Buy → Hold	$23 → $18
Oct-29-25	Downgrade	Canaccord Genuity	Buy → Hold	$29 → $15
Oct-28-25	Reiterated	Evercore ISI	In Line	$18
Oct-27-25	Reiterated	Jefferies	Buy	$27 → $23
Oct-24-25	Reiterated	Deutsche Bank	Hold	$20 → $18

Company

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/28/2025	FY 2024 12/29/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	15,292	15,124	15,455	15,444	14,950	15,054	14,467	14,324
Cost of Goods Sold Incl. D&A	6,366	6,332	6,496	6,801	6,665	6,635	6,619	6,662
Gross Profit	8,926	8,792	8,959	8,643	8,285	8,419	7,848	7,662
Selling, General and Administrative Excl. Other	6,004	6,088	6,027	6,141	5,633	5,484	4,956	5,198
Research and Development	84	382	0	0	0	0	0	0
Other Operating Expense	-157	-382	1,091	-10	-23	15	3,871	618
Operating Income	3,001	2,704	1,841	2,512	2,675	2,920	-979	1,846
Interest Expense	393	379	431	358	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-395	-326	5	36	-38	5	-37	274
Net Income Before Taxes	2,213	1,999	1,415	2,190	2,637	2,925	-1,016	2,120
Income Taxes	591	529	385	526	573	847	-137	685
Consolidated Net Income	1,622	1,470	1,030	1,664	2,064	2,078	-879	1,435
Net Income From Continuing Operations	1,622	1,470	1,030	1,664	2,064	2,078	-879	1,435
Net Income	1,622	1,470	1,030	1,664	2,064	2,078	-879	1,435
EPS (Recurring)	0.85	0.77	0.54	0.90	1.08	1.10	-0.47	0.76
EPS (Basic, Before Extraordinaries)	0.85	0.77	0.54	0.90	1.08	1.10	-0.47	0.76
EPS (Diluted)	0.85	0.76	0.54	0.87	1.08	1.10	-0.47	0.76
EBITDA	3,170	2,935	2,468	3,175	3,281	3,656	3,734	3,108
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	22.68	22.62	39.87	24.75	—	—	—	—
Price To Sales Ratio	2.42	2.18	2.67	2.58	—	—	—	—
Gross Margin	58.37	58.13	57.97	55.96	55.42	55.93	54.25	53.49
Operating Margin	19.62	17.88	11.91	16.27	17.89	19.40	-6.77	12.89
Net Margin	10.61	9.72	6.66	10.77	13.81	13.80	-6.08	10.02
Shares Outstanding	1,918	1,917	1,915	1,849	1,915	1,889	1,889	1,889
Market Capitalization	36,979	32,953	41,230	39,809	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Howlett Heather	CFO & CAO	Jun 10 '26	Sale	18.11	3,700	66,989	29,288	Jun 12
Curado Gomes de Lemos Leonardo	Group President LATAM	May 01 '26	Option Exercise	0.00	24,248	0	24,248	May 26
Orlando Matthew	General Counsel	May 08 '26	Sale	17.66	38,491	679,691	0	May 12
Alvarado Luani	Chief People Officer	Mar 10 '26	Option Exercise	0.00	4,222	0	62,797	Mar 12
Lawson Carlton	Group President EMEA & LA	Mar 10 '26	Option Exercise	0.00	6,158	0	111,415	Mar 12
Stevens Meredith	Chief Operations Officer	Mar 10 '26	Option Exercise	0.00	5,169	0	94,877	Mar 12
Lawson Carlton	Group President EMEA & LA	Mar 05 '26	Option Exercise	0.00	7,736	0	105,257	Mar 09
Alvarado Luani	Chief People Officer	Mar 05 '26	Option Exercise	0.00	4,289	0	61,365	Mar 09
Stevens Meredith	Chief Operations Officer	Mar 05 '26	Option Exercise	0.00	6,178	0	92,224	Mar 09
Howlett Heather	VP & Chief Accounting Officer	Mar 05 '26	Option Exercise	0.00	2,723	0	33,921	Mar 09
Howlett Heather	VP & Chief Accounting Officer	Mar 03 '26	Option Exercise	0.00	1,534	0	31,725	Mar 04
Stevens Meredith	Chief Operations Officer	Feb 13 '26	Option Exercise	0.00	28,040	0	90,862	Feb 18
Alvarado Luani	Chief People Officer	Feb 13 '26	Option Exercise	0.00	15,942	0	60,722	Feb 18
Lawson Carlton	Group President EMEA & LA	Feb 13 '26	Option Exercise	16.52	39,426	651,365	97,521	Feb 18
Howlett Heather	VP & Chief Accounting Officer	Feb 13 '26	Option Exercise	0.00	13,571	0	33,284	Feb 18